Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco Pharma
30 tablet
Gefitinib
Keep in cold place
Delivering To:
Overview
Non-small cell lung cancer is treated with Geftinat 250 mg tablets. Patients who have not received previous cancer treatment, have abnormal epidermal growth factor receptor (EGFR) genes, and whose cancer has progressed to other parts of their body are treated with it. It has a 250 mg dose of gefitinib. An anticancer medication called Geftinat 250mg Tablet is recommended to treat lung cancer.
non-small cell lung cancer (NSCLC)
Non-small cell lung cancer
Geftinat 250mg Tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.
Diarrhea
Fever
Allergic skin reaction
Nausea and Vomiting
Increase in liver enzyme levels
Eye irritation
Difficulty in breathing
Abdominal pain
Sore throat
Redness around fingernails
Unusual bleeding (in cough and urine), eye irritation or pain, swelling of the ankles or feet
The doctor will recommend the dose strength and frequency of your dose as per your health condition and the body’s tolerance. Take the capsule as a whole with water. Do not crush or cut it. Get emergency medical treatment and contact your physician in case of overdose.
Geftinat 250mg Tablet works by inhibiting the intracellular phosphorylation of tyrosine kinase associated with epidermal growth factor (EGFR). It contains Gefitinib in 250mg strength. It works by blocking the abnormal protein that causes cancer cells to proliferate from doing its job. This can help prevent or stop the growth of cancerous cells.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Geftinat 250mg Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Geftinat 250mg Tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
If a patient misses a dose of medicine, skip it and continue with the normal schedule. No need to double the dose
Geftinat 250mg Tablet is an anticancer medicine used for the treatment of cancer of the lungs. Take the medicine under the supervision of a qualified physician. This medicine is not recommended for use in patients with lung and liver diseases.
Epidermal growth factor receptors (EGFR) are expressed on the lung cancer cell surfaces that regulate their growth. This medicine works by binding the chemical messenger, EGFR, thus inhibiting the cancer signaling pathways. This is how the medicine inhibits further growth of the cancer cells.
Side Effects of this medicine include nausea, rash, vomiting, and weight loss. It may cause severe diarrhea, drink plenty of fluids or consult the doctor if it happens. It makes the patient sensitive to sunlight, hence wear protective clothing or use sunscreen while going out.
This tablet is a pill to be administered orally, once a day without food as prescribed by the concerned specialist. Take Geftinat 250mg Tablet empty stomach, at least 1 hour before or 2 hours after meals. Take it at the same time each day so that you remember when to take it
Do not drive if you have any symptoms that affect your ability to concentrate and react. Geftinat 250mg Tablet makes you feel weak. This may affect your driving ability.
if gefitinib or any other ingredient in this medication causes allergies in you. If you have any drug allergies, let your doctor know. Be sure to mention the allergy and any symptoms you experienced. This includes reporting any symptoms, such as a rash, hives, itching, wheezing, shortness of breath, coughing, or swelling of the face, lips, tongue, or neck. if you are or might become pregnant. if you are nursing a child.
Keep out of children's reach in a cold, dry location. It is not permitted to take medications after their expiration date.
Ghosh, R., Rajendranath, R., & Ganesan, P. (2019). A comparative observational study on erlotinib and gefitinib in NSCLC: Tolerability and clinical outcomes in Indian patients. Indian Journal of Medical and Paediatric Oncology, 40(4), 100-500.
Louis, R. A., Rajendranath, R., Ganesan, P., Sagar, T. G., & Krishnamurthy, A. (2012). First report of upfront gefitinib compared with chemotherapy in advanced NSCLC patients from South India: Analysis of 120 patients. Indian Journal of Medical & Paediatric Oncology, 33(3), 146–154.
Singh, A., Patil, V., Menon, N., More, S., Jain, S., Goud, S., Shah, D., Shah, M., Jobanputra, K., & Ubharay, A. (2024). Long-term survival outcomes of gefitinib (Geftinat®) 250 mg versus carboplatin–pemetrexed chemotherapy in EGFR‑mutated advanced non‑small cell lung cancer: A Phase III randomized trial. Cancer Research, Statistics, and Treatment, 7(1), 19–26.
Singh, A., Patil, V., Menon, N., More, S., Jain, S., Goud, S., Shah, D., Shah, M., Jobanputra, K., & Ubharay, A. (2024). Long‑term survival outcomes of gefitinib (Geftinat®) 250 mg versus carboplatin–pemetrexed chemotherapy in EGFR‑mutated advanced non‑small cell lung cancer: A Phase III randomized trial. Cancer Research, Statistics, and Treatment, 7(1), 19–26.
Talvar, V., Vaid, A. K., Doval, D. C., Gupta, S., Sharma, J. B., & Sarin, J. (2006). EGFR inhibitor gefitinib in advanced pretreated non‑small cell lung cancer patients: Experience from a centre in North India. Journal of Clinical Oncology, 24(18), 17141.
